{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:44:57Z","timestamp":1784292297151,"version":"3.55.0"},"reference-count":19,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Annual iv administration of 5 mg zoledronate decreases fracture risk. The optimal dosing interval of 5 mg zoledronate is not known.<\/jats:p>\n               <jats:p>Objective: Our objective was to determine the duration of antiresorptive action of a single 5-mg dose of iv zoledronate.<\/jats:p>\n               <jats:p>Design, Setting, and Participants: We conducted a double-blind, randomized, placebo-controlled trial over 2 yr at an academic research center, in a volunteer sample of 50 postmenopausal women with osteopenia.<\/jats:p>\n               <jats:p>Intervention: Intervention included 5 mg zoledronate.<\/jats:p>\n               <jats:p>Main Outcome Measures: Biochemical markers of bone turnover and bone mineral density of the lumbar spine, proximal femur, and total body.<\/jats:p>\n               <jats:p>Results: Compared with placebo, zoledronate treatment decreased mean levels of each of four markers of bone turnover by at least 38% (range 38\u201345%) for the duration of the study (P &amp;lt; 0.0001 for each marker). After 2 yr, bone mineral density was higher in the zoledronate group than the placebo group by an average of 5.7% (95% confidence interval = 4.0\u20137.4) at the lumbar spine, 3.9% (2.2\u20135.7) at the proximal femur, and 1.7% (0.8\u20132.5) at the total body (P &amp;lt; 0.0001 for each skeletal site). Between-groups differences in markers of bone turnover and bone mineral density were similar at 12 and 24 months. Mild secondary hyperparathyroidism was present throughout the study in the zoledronate group.<\/jats:p>\n               <jats:p>Conclusion: The antiresorptive effects of a single 5-mg dose of zoledronate are sustained for at least 2 yr. The magnitudes of the effects on markers of bone turnover and bone mineral density are comparable at 12 and 24 months. Administration of zoledronate at intervals of up to 2 yr may be associated with antifracture efficacy; clinical trials to investigate this possibility are justified.<\/jats:p>","DOI":"10.1210\/jc.2008-2241","type":"journal-article","created":{"date-parts":[[2008,12,3]],"date-time":"2008-12-03T03:04:44Z","timestamp":1228273484000},"page":"538-544","source":"Crossref","is-referenced-by-count":95,"title":["The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women"],"prefix":"10.1210","volume":"94","author":[{"given":"Andrew","family":"Grey","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Bolland","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Wattie","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horne","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Gamble","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R.","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071614232407500_R1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071614232407500_R2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture.","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071614232407500_R3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density.","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"2020071614232407500_R4","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00198-007-0367-3","article-title":"Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.","volume":"18","author":"Devogelaer","year":"2007","journal-title":"Osteoporos Int"},{"key":"2020071614232407500_R5","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1359\/jbmr.080312","article-title":"Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.","volume":"23","author":"Bolland","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2020071614232407500_R6","first-page":"S343","article-title":"Effects of ibandronate i.v","volume":"12","author":"Thie\u0301baud","year":"1997","journal-title":"bolus injection in healthy men and postmenopausal women. J Bone Miner Res"},{"key":"2020071614232407500_R7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials.","volume":"39","author":"O'Brien","year":"1979","journal-title":"Biometrics"},{"key":"2020071614232407500_R8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2020071614232407500_R9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1742-1241.2007.01392.x","article-title":"Bone turnover 18 months after a single intravenous dose of zoledronic acid.","volume":"61","author":"Borba","year":"2007","journal-title":"Int J Clin Pract"},{"key":"2020071614232407500_R10","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-07-0247","article-title":"Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.","volume":"13","author":"Brown","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2020071614232407500_R11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.","volume":"23","author":"Recker","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071614232407500_R12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2020071614232407500_R13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"2020071614232407500_R14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","article-title":"Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.","volume":"15","author":"Recker","year":"2004","journal-title":"Osteoporos Int"},{"key":"2020071614232407500_R15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.bone.2006.09.010","article-title":"Effects of cyclic vs. daily treatment with human parathyroid hormone (1\u201334) on murine bone structure and cellular activity.","volume":"40","author":"Iida-Klein","year":"2007","journal-title":"Bone"},{"key":"2020071614232407500_R16","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1359\/jbmr.2003.18.12.2116","article-title":"Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment.","volume":"18","author":"Kim","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071614232407500_R17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s001980200026","article-title":"The anabolic effects of parathyroid hormone.","volume":"13","author":"Rubin","year":"2002","journal-title":"Osteoporos Int"},{"key":"2020071614232407500_R18","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"2020071614232407500_R19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis.","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/2\/538\/9059230\/jcem0538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/2\/538\/9059230\/jcem0538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T02:09:43Z","timestamp":1594951783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/2\/538\/2598311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-2241","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}